Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAGLPW)

• Drug Name: RO-316233 Drug Info
• Synonyms: 119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 2399
  ChEBI ID: CHEBI:92857
  CAS Number: CAS 119139-23-0
  TTD Drug ID: DMAGLPW

Molecule-Related Drug Atlas

Drug(s) Targeting Protein kinase C epsilon (PRKCE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meprobamate	DMHM93Y	Anxiety		Approved	[11]
Bryostatin-1	DM1JOXY	Alzheimer disease	8A20	Phase 2	[12]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[13]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[14]
CDE-6960	DMA0DKI	Inflammation	1A00-CA43.1	Terminated	[15]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[16]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[16]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[16]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[16]
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[17]

Drug(s) Targeting cAMP-dependent protein kinase A type I (PRKAR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
[3H]cAMP	DMZRQU7	Discovery agent	N.A.	Investigative	[18]
AdoC(Dpr)2AlaArg6	DM2TWSZ	Discovery agent	N.A.	Investigative	[19]
AdcAhxArg4NH(CH2)6NH2	DMSYMRJ	Discovery agent	N.A.	Investigative	[20]
AdcAhxArg4Lys-PEGOMe	DMQ2C8X	Discovery agent	N.A.	Investigative	[20]
AdoC(GABA)Arg6	DMMWNPT	Discovery agent	N.A.	Investigative	[19]
AdcAhxArg4Lys(biotin)-PEG-OMe	DMZYJHV	Discovery agent	N.A.	Investigative	[20]
AdoC(Aun)Arg6	DMDLHAB	Discovery agent	N.A.	Investigative	[19]
Cyclic Guanosine Monophosphate	DMOU93V	Discovery agent	N.A.	Investigative	[18]
AdoCGlyArg6	DMVQJP0	Discovery agent	N.A.	Investigative	[19]
AdoC(Aoc)Arg6	DMRSCO2	Discovery agent	N.A.	Investigative	[19]

Drug(s) Targeting LCK tyrosine protein kinase (LCK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[21]
VX-680	DM93YKJ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[21]
JNJ-26483327	DMSQ3AZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[22]
ISIS-CRP	DMQDUG4	Cardiovascular disease	BA00-BE2Z	Phase 1	[23]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[3]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[24]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[3]
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[25]
BMS-536924	DMXJB4N	Discovery agent	N.A.	Investigative	[26]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Protein kinase C alpha (PRKCA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[27]
Sotrastaurin acetate	DME53YS	Renal transplantation	NE84	Phase 2	[28]
PMID28460551-Compound-3	DMA1FRM	N. A.	N. A.	Patented	[29]
ISIS 3521	DMZFS69	N. A.	N. A.	Discontinued in Phase 2	[30]
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[31]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[13]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[14]
Acteoside	DM0YHKB	Nephritis	GB40	Terminated	[32]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[24]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting NAD-dependent deacetylase sirtuin-1 (SIRT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[33]
GSK2245840	DMG7YQL	Chronic obstructive pulmonary disease	CA22	Phase 2	[34]
SEN-196	DMLDBQ5	Huntington disease	8A01.10	Phase 2	[35]
MB-12066	DMRSN2C	Obesity	5B81	Phase 2	[36]
SRT2379	DM7DAKX	Type-2 diabetes	5A11	Phase 1	[37]
SRT3025	DMRAXFH	Type-2 diabetes	5A11	Phase 1	[38]
PMID25435179-Compound-WO2012106509Salermide	DMLAH39	N. A.	N. A.	Patented	[33]
CAMBINOL	DMW46GY	Discovery agent	N.A.	Patented	[39]
PMID25435179-Compound-WO2012106509CAY10602	DM2F1T0	N. A.	N. A.	Patented	[33]
PMID25435179-Compound-WO2012106509Tenovin-6	DMBSOED	N. A.	N. A.	Patented	[33]

Drug(s) Targeting Protein kinase C theta (PRKCQ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sotrastaurin acetate	DME53YS	Renal transplantation	NE84	Phase 2	[28]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[13]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[14]
CDE-6960	DMA0DKI	Inflammation	1A00-CA43.1	Terminated	[15]
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[17]
L-serine-O-phosphate	DMTJ1NH	Discovery agent	N.A.	Investigative	[18]
[2,2':5',2'']Terthiophen-4-yl-methanol	DMRQC1F	Discovery agent	N.A.	Investigative	[40]
4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol	DM8IYG1	Discovery agent	N.A.	Investigative	[41]
2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile	DMNGW1A	Discovery agent	N.A.	Investigative	[41]
[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde	DMWDNLI	Discovery agent	N.A.	Investigative	[40]

Drug(s) Targeting Stress-activated protein kinase JNK1 (JNK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NKP-1339	DM5AWK1	Solid tumour/cancer	2A00-2F9Z	Phase 1	[42]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[43]
PMID25991433-Compound-F2	DM37VIQ	N. A.	N. A.	Patented	[43]
7-azaindole derivative 1	DMQL5B7	N. A.	N. A.	Patented	[43]
7-azaindole derivative 5	DMV3H98	N. A.	N. A.	Patented	[43]
PMID25991433-Compound-P6	DMNDVC9	N. A.	N. A.	Patented	[43]
PMID25991433-Compound-J3	DM17P3F	N. A.	N. A.	Patented	[43]
PMID25991433-Compound-P1	DMD8AX6	N. A.	N. A.	Patented	[43]
PMID25991433-Compound-O3	DMVOWS5	N. A.	N. A.	Patented	[43]
PMID25991433-Compound-L1	DM2135Y	N. A.	N. A.	Patented	[43]

Drug(s) Targeting Protein kinase C beta (PRKCB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enzastaurin	DM5H0R9	Diffuse large B-cell lymphoma	2A81	Phase 3	[44]
RUBOXISTAURIN HYDROCHLORIDE	DMQOCD8	Lymphoma	2A80-2A86	Phase 3	[45]
Sotrastaurin acetate	DME53YS	Renal transplantation	NE84	Phase 2	[28]
LY333531	DMGMC8H	Solid tumour/cancer	2A00-2F9Z	Phase 2	[46]
MS-553	DM7ER9J	Chronic lymphocytic leukaemia	2A82.0	Phase 1	[47]
Linetastine	DMF8B62	Rhinitis	FA20	Discontinued in Phase 2	[48]
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[31]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[13]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[14]
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[17]

Drug(s) Targeting Protein kinase C delta (PRKCD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KAI-9803	DMELJDI	Acute myocardial infarction	BA41	Phase 1/2	[49]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[13]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[14]
AD 198	DMJFY2I	N. A.	N. A.	Terminated	[50]
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[17]
PROSTRATIN	DM1HMJ5	Human immunodeficiency virus infection	1C62	Investigative	[51]
[2,2':5',2'']Terthiophen-4-yl-methanol	DMRQC1F	Discovery agent	N.A.	Investigative	[40]
4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol	DM8IYG1	Discovery agent	N.A.	Investigative	[41]
2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile	DMNGW1A	Discovery agent	N.A.	Investigative	[41]
[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde	DMWDNLI	Discovery agent	N.A.	Investigative	[40]

Drug(s) Targeting Protein kinase C gamma (PRKCG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[21]
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[31]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[13]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[14]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[52]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[16]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[16]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[16]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[16]
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[17]

Drug(s) Targeting Cyclin-dependent kinase 1 (CDK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[53]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[21]
P276-00	DM9DJL2	Mantle cell lymphoma	2A85.5	Phase 2	[53]
P-276	DMMJUHD	Breast cancer	2C60-2C65	Phase 2	[54]
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[55]
AG-024322	DMY4WVK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[53]
PHA-793887	DM2Y4FG	Solid tumour/cancer	2A00-2F9Z	Phase 1	[56]
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[57]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[43]
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[58]

Drug(s) Targeting Rho-associated protein kinase 1 (ROCK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Netarsudil	DM0LPI9	Open-angle glaucoma	9C61	Approved	[59]
SAR-407899	DMF95KD	Diabetic nephropathy	GB61.Z	Phase 2	[60]
H-1152	DM8XH3S	Pulmonary arterial hypertension	BB01.0	Phase 2	[61]
INS-117548	DMA46DO	Glaucoma/ocular hypertension	9C61	Phase 1	[62]
GSK269962A	DM5I2HL	Inflammation	1A00-CA43.1	Clinical trial	[63]
PMID28048944-Compound-19	DMPT3V9	N. A.	N. A.	Patented	[64]
PMID28048944-Compound-3	DM1BN74	N. A.	N. A.	Patented	[64]
PMID28048944-Compound-7	DMXZ368	N. A.	N. A.	Patented	[64]
PMID28048944-Compound-4	DMJAUWG	N. A.	N. A.	Patented	[64]
PMID28048944-Compound-5	DMAB987	N. A.	N. A.	Patented	[64]

Drug(s) Targeting Stress-activated protein kinase 2b (p38 beta)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[65]
SB 235699	DMNH8XU	Psoriasis vulgaris	EA90	Discontinued in Phase 1	[65]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[3]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[24]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[3]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[3]
Ro31-8220	DMDJLF0	Discovery agent	N.A.	Investigative	[3]
STAUROSPORINONE	DMU2H4K	Discovery agent	N.A.	Investigative	[3]
KT-5720	DM9J50F	Discovery agent	N.A.	Investigative	[3]
L-779450	DM51B74	Discovery agent	N.A.	Investigative	[66]

Drug(s) Targeting Extracellular signal-regulated kinase 2 (ERK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BVD-523	DMNB4XK	Melanoma	2C30	Phase 2	[67]
HH2710	DM0C5MV	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[68]
ASTX029	DMVZXIA	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[69]
VAN-10-4-eluting stent	DM3ZW6A	Artery stenosis	BD52	Phase 1	[70]
GDC-0994	DMFC2OY	Solid tumour/cancer	2A00-2F9Z	Phase 1	[71]
JSI-1187	DMVJWBS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[72]
LY3214996	DMFDAY7	Solid tumour/cancer	2A00-2F9Z	Phase 1	[73]
CHIR-99021	DMB8MNU	Allergic inflammation	4A80-4A85	Patented	[74]
COR-D	DMLXMCB	T-cell leukaemia	2A90	Preclinical	[75]
SB220025	DMSBUET	Arthritis	FA20	Terminated	[18]

Drug(s) Targeting Protein kinase C zeta (PRKCZ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methyl 2-amino-4-phenylthiophene-3-carboxylate	DM9BYJ0	N. A.	N. A.	Patented	[76]
Y-9680	DMHAVYS	N. A.	N. A.	Patented	[76]
US8889696, 39	DMKXRJ4	N. A.	N. A.	Patented	[77]
US8889672, 252-036-001	DM8B1Q4	N. A.	N. A.	Patented	[76]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[13]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[14]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[78]
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[17]
[2,2':5',2'']Terthiophen-4-yl-methanol	DMRQC1F	Discovery agent	N.A.	Investigative	[40]
4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol	DM8IYG1	Discovery agent	N.A.	Investigative	[41]

Drug(s) Targeting Checkpoint kinase-1 (CHK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY2603618	DMCXRZF	Pancreatic cancer	2C10	Phase 2	[79]
UCN-01	DMUNJZB	Non-small-cell lung cancer	2C25.Y	Phase 2	[80]
SCH-900776	DM67EMK	Solid tumour/cancer	2A00-2F9Z	Phase 2	[81]
LY2606368	DM4XMF7	Ovarian cancer	2C73	Phase 2	[73]
LY2880070	DMADEHZ	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[82]
RG7741	DMK6P9J	Lymphoma	2A80-2A86	Phase 1	[83]
GDC-0425	DMDZ26X	Lymphoma	2A80-2A86	Phase 1	[84]
AZD7762	DM1FW0C	Solid tumour/cancer	2A00-2F9Z	Phase 1	[85]
MK-8776	DMAS1RB	Hodgkin lymphoma	2B30	Phase 1	[86]
Diamidothiazole derivative 1	DM02V5Q	N. A.	N. A.	Patented	[57]

Drug(s) Targeting Serine/threonine-protein kinase Sgk1 (SGK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[3]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[24]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[3]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[3]
CGP-57380	DMFPOUC	Discovery agent	N.A.	Investigative	[23]
GSK-650394	DMNRP2L	Prostate cancer	2C82.0	Investigative	[87]

Drug(s) Targeting Stress-activated protein kinase 2a (p38 alpha)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ozagrel	DMIGKA1	Xerophthalmia	5B55.Y	Phase 4	[88]
Losmapimod	DMIL37Z	Acute coronary syndrome	BA41	Phase 3	[88]
VX-702	DMKJDR6	Coronary artery disease	BA80	Phase 2a	[89]
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[65]
Dilmapimod	DMBYJ92	Acute lung injury	NB32.3	Phase 2	[88]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[43]
PMID25991433-Compound-F2	DM37VIQ	N. A.	N. A.	Patented	[43]
PMID25991433-Compound-L2	DM58UO9	N. A.	N. A.	Patented	[43]
PMID25991433-Compound-L3	DM3LWUR	N. A.	N. A.	Patented	[43]
PMID25991433-Compound-L1	DM2135Y	N. A.	N. A.	Patented	[43]

Drug(s) Targeting RAC-alpha serine/threonine-protein kinase (AKT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[73]
Enzastaurin	DM5H0R9	Diffuse large B-cell lymphoma	2A81	Phase 3	[73]
GDC-0068	DMWBZJD	Breast cancer	2C60-2C65	Phase 3	[73]
CI-1033	DMSI8N3	Lymphoma	2A80-2A86	Phase 2	[21]
CMX-2043	DMPSCVY	Cardiac disease	BA00-BE2Z	Phase 2	[90]
ARQ 092	DM5WK0J	Proteus syndrome	LD2C	Phase 2	[91]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[92]
RX-0201	DMTBAV3	Pancreatic cancer	2C10	Phase 2	[93]
PTX-200	DM0ZIT2	Breast cancer	2C60-2C65	Phase 2	[73]
Triciribine prodrug	DMBN1XS	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[92]

Drug(s) Targeting MAP kinase p38 (MAPK12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SM-101	DMFX9O6	Idiopathic thrombocytopenic purpura	3B64.10	Approved (orphan drug)	[94]
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[95]
ARRY-797	DMJ48AB	Dilated cardiomyopathy	BC43.0	Phase 2	[96]
KC706	DMBX6C7	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 2	[97]
SB 235699	DMNH8XU	Psoriasis vulgaris	EA90	Discontinued in Phase 1	[98]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[3]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[24]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[3]
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[25]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting PKC-epsilon messenger RNA (PRKCE mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[31]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[52]
PROSTRATIN	DM1HMJ5	Human immunodeficiency virus infection	1C62	Investigative	[51]
8-Octyl-benzolactam-V9	DM4Z15M	Discovery agent	N.A.	Investigative	[99]
chelerythrine	DMCP1G9	Discovery agent	N.A.	Investigative	[100]
ISIS 7942	DMN0A1R	Discovery agent	N.A.	Investigative	[101]
ISIS 7948	DMYZE8R	Discovery agent	N.A.	Investigative	[101]

Drug(s) Targeting Ribosomal protein S6 kinase beta-1 (S6K1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
M2698	DM3PVBJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[73]
NNI-362	DMPCV65	Alzheimer disease	8A20	Phase 1	[102]
PF-4708671	DMO0892	Ulcerative colitis	DD71	Clinical trial	[103]
PMID27410995-Compound-Figure3c	DMDQMZT	N. A.	N. A.	Patented	[104]
Pyrimido[4,5-d] pyrimidines and pyrido[4,3-d] pyrimidine derivative 1	DM6O2Q9	N. A.	N. A.	Patented	[104]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[105]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[24]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[3]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[3]
Ro31-8220	DMDJLF0	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting G2/mitotic-specific cyclin B1 (CCNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[58]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[4]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[16]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[16]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[16]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[16]
AZAKENPAULLONE	DM61H07	Discovery agent	N.A.	Investigative	[106]
Thieno analogue of kenpaullone	DMIOTHG	Discovery agent	N.A.	Investigative	[106]
3,4-bis(indol-3-yl)maleimide derivative	DMEQ1HC	Discovery agent	N.A.	Investigative	[4]
4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine	DMDW3SX	Discovery agent	N.A.	Investigative	[107]

Drug(s) Affected By Aromatase (CYP19A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[108]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[109]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[110]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[111]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[110]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[112]
FADROZOLE	DM3C5GZ	Breast cancer	2C60-2C65	Approved	[113]
Bifonazole	DM3KN7V	Fungal infection	1F29-1F2F	Approved	[114]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[115]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[110]

Drug(s) Affected By Telomerase reverse transcriptase (TERT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[116]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[117]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[118]
Selenium	DM25CGV	N. A.	N. A.	Approved	[119]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[120]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[121]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[122]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[123]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[124]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[125]

Drug(s) Affected By RalA-binding protein 1 (RALBP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[126]
Selenium	DM25CGV	N. A.	N. A.	Approved	[127]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[128]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[129]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[130]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[131]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[132]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[133]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[134]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[135]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
cAMP-dependent protein kinase A type I (PRKAR1A)	TTNAHEX	KAP0_HUMAN	Inhibitor	[2]
Checkpoint kinase-1 (CHK1)	TTTU902	CHK1_HUMAN	Inhibitor	[3]
Cyclin-dependent kinase 1 (CDK1)	TTH6V3D	CDK1_HUMAN	Inhibitor	[4]
Extracellular signal-regulated kinase 2 (ERK2)	TT4TQBX	MK01_HUMAN	Inhibitor	[3]
G2/mitotic-specific cyclin B1 (CCNB1)	TT9P6OW	CCNB1_HUMAN	Inhibitor	[4]
LCK tyrosine protein kinase (LCK)	TT860QF	LCK_HUMAN	Inhibitor	[3]
MAP kinase p38 (MAPK12)	TTYT93M	MK12_HUMAN	Inhibitor	[3]
NAD-dependent deacetylase sirtuin-1 (SIRT1)	TTUF2HO	SIR1_HUMAN	Inhibitor	[5]
PKC-epsilon messenger RNA (PRKCE mRNA)	TT57MT2	KPCE_HUMAN	Inhibitor	[6]
Protein kinase C alpha (PRKCA)	TTFJ8Q1	KPCA_HUMAN	Inhibitor	[2]
Protein kinase C beta (PRKCB)	TTYPXQF	KPCB_HUMAN	Inhibitor	[2]
Protein kinase C delta (PRKCD)	TT9WJ8U	KPCD_HUMAN	Inhibitor	[2]
Protein kinase C epsilon (PRKCE)	TTBZ7OD	KPCE_HUMAN	Inhibitor	[2]
Protein kinase C gamma (PRKCG)	TTRFOXJ	KPCG_HUMAN	Inhibitor	[2]
Protein kinase C theta (PRKCQ)	TT8QL1J	KPCT_HUMAN	Inhibitor	[2]
Protein kinase C zeta (PRKCZ)	TTUWGRA	KPCZ_HUMAN	Inhibitor	[2]
RAC-alpha serine/threonine-protein kinase (AKT1)	TTWTSCV	AKT1_HUMAN	Inhibitor	[3]
Rho-associated protein kinase 1 (ROCK1)	TTZN7RP	ROCK1_HUMAN	Inhibitor	[3]
Ribosomal protein S6 kinase beta-1 (S6K1)	TTG0U4H	KS6B1_HUMAN	Inhibitor	[3]
Serine/threonine-protein kinase Sgk1 (SGK1)	TTTV8EJ	SGK1_HUMAN	Inhibitor	[3]
Stress-activated protein kinase 2a (p38 alpha)	TTQBR95	MK14_HUMAN	Inhibitor	[3]
Stress-activated protein kinase 2b (p38 beta)	TT73U6C	MK11_HUMAN	Inhibitor	[3]
Stress-activated protein kinase JNK1 (JNK1)	TT0K6EO	MK08_HUMAN	Inhibitor	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Aromatase (CYP19A1)	OTZ6XF74	CP19A_HUMAN	Gene/Protein Processing	[7]
RalA-binding protein 1 (RALBP1)	OTBIGB1D	RBP1_HUMAN	Post-Translational Modifications	[8]
Telomerase reverse transcriptase (TERT)	OT085VVA	TERT_HUMAN	Gene/Protein Processing	[9]
UL16-binding protein 1	OTUIBJD0	ULBP1_HUMAN	Gene/Protein Processing	[10]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5937).
• [2] Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
• [3] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [4] Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22.
• [5] Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J Med Chem. 2006 Dec 14;49(25):7307-16.
• [6] Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5171-4.
• [7] Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue. J Steroid Biochem Mol Biol. 2005 May;95(1-5):17-23.
• [8] The role of PKCalpha and RLIP76 in transport-mediated doxorubicin-resistance in lung cancer. FEBS Lett. 2005 Aug 29;579(21):4635-41. doi: 10.1016/j.febslet.2005.07.032.
• [9] Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture. Biochem Biophys Res Commun. 1997 Dec 29;241(3):730-6. doi: 10.1006/bbrc.1997.7874.
• [10] Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction. Cancer Sci. 2012 Jan;103(1):7-16. doi: 10.1111/j.1349-7006.2011.02109.x. Epub 2011 Nov 15.
• [11] Protein kinase C, an elusive therapeutic target . Nat Rev Drug Discov. 2012 December; 11(12): 937-957.
• [12] Protein kinase epsilon dampens the secretory response of model intestinal epithelia during ischemia. Surgery. 2001 Aug;130(2):310-8.
• [13] Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
• [14] Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025002)
• [16] Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
• [17] (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
• [18] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [19] Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
• [20] Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9.
• [21] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [22] National Cancer Institute Drug Dictionary (drug id 596693).
• [23] The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
• [24] Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
• [25] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [26] Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
• [27] Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401.
• [28] Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
• [29] Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
• [30] Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.Lung Cancer.2006 May;52(2):173-80.
• [31] Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
• [32] Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2.
• [33] Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
• [34] Sirtuin 1 activator SRT2104 protects Huntington's disease mice. Ann Clin Transl Neurol. 2014 Dec;1(12):1047-52.
• [35] Sirtuin 1 (SIRT1): the misunderstood HDAC. J Biomol Screen. 2011 Dec;16(10):1153-69.
• [36] Pharmacological activation of Sirt1 ameliorates polyglutamine-induced toxicity through the regulation of autophagy.PLoS One.2013 Jun 10;8(6):e64953.
• [37] SRT2379, a small-molecule SIRT1 activator, fails to reduce cytokine release in a human endotoxemia model. Critical Care 2013, 17(Suppl 4):P8.
• [38] The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One. 2015 Jul 30;10(7):e0134391.
• [39] Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J Med Chem. 2009 May 14;52(9):2673-82.
• [40] Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.
• [41] Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
• [42] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1496).
• [43] c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
• [44] The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma. 2008 Jul;49(7):1374-83.
• [45] Ruboxistaurin: LY 333531. Drugs R D. 2007;8(3):193-9.
• [46] Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes. 2003 Feb;52(2):512-8.
• [47] ClinicalTrials.gov (NCT03492125) A Study Of The Selective PKC-beta Inhibitor MS- 553. U.S. National Institutes of Health.
• [48] Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol. 2002 May;133(5):693-8.
• [49] PKC delta and epsilon in drug targeting and therapeutics. Recent Pat DNA Gene Seq. 2009;3(2):96-101.
• [50] Novel extranuclear-targeted anthracyclines override the antiapoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis. Mol Cancer Ther. 2002 May;1(7):469-81.
• [51] A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86.
• [52] Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2... J Biol Chem. 2007 Nov 9;282(45):33052-63.
• [53] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [54] P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
• [55] Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
• [56] A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
• [57] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [58] Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30.
• [59] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [60] The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012 May;30(5):980-9.
• [61] Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
• [62] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [63] Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.
• [64] Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
• [65] Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
• [66] The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81.
• [67] DOI: 10.1158/1538-7445.AM2015-4693
• [68] Clinical pipeline report, company report or official report of HaiHe Biopharma.
• [69] Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
• [70] WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
• [71] ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
• [72] National Cancer Institute Drug Dictionary (drug name JSI1187).
• [73] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [74] Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
• [75] Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
• [76] Compounds, formulations, and methods of protein kinase C inhibition. US8889672.
• [77] Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof. US8889696.
• [78] Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines. J Neurooncol. 2000 Apr;47(2):109-15.
• [79] Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26.
• [80] Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening app... J Mol Graph Model. 2009 Sep;28(2):113-30.
• [81] Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
• [82] A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3581-3581.
• [83] National Cancer Institute Drug Dictionary (drug id 730054).
• [84] Quantitative assessment of BCL-2:BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199).
• [85] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [86] Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. Int J Mol Sci. 2019 Aug 22;20(17):4095.
• [87] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8040).
• [88] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [89] Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
• [90] Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64.
• [91] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [92] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
• [93] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [94] Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
• [95] P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond). 2008 Dec 4;5:22.
• [96] Array BioPharmas ARRY-797 Meets Primary Endpoint in Clinical Proof of Concept Trial in Osteoarthritis Patients Whose Pain is Poorly Controlled by NSAIDs
• [97] KC706, an Oral p38 MAP Kinase Inhibitor, Increases HDL-C. Circulation. 2007;116:II_126.
• [98] Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J Med Chem. 2003 Dec 18;46(26):5651-62.
• [99] Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta. J Med Chem. 2006 May 4;49(9):2681-8.
• [100] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
• [101] US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
• [102] Novel pharmacotherapy: NNI-362, an allosteric p70S6 kinase stimulator, reverses cognitive and neural regenerative deficits in models of aging and disease. Stem Cell Res Ther. 2021 Jan 13;12(1):59.
• [103] Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J. 2010 Oct 15;431(2):245-55.
• [104] Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
• [105] 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
• [106] 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
• [107] Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives. Eur J Med Chem. 2010 Jan;45(1):379-86.
• [108] Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res. 2005 Apr 15;11(8):2809-21. doi: 10.1158/1078-0432.CCR-04-2187.
• [109] Cannabidiol (CBD) but not tetrahydrocannabinol (THC) dysregulate in vitro decidualization of human endometrial stromal cells by disruption of estrogen signaling. Reprod Toxicol. 2020 Apr;93:75-82. doi: 10.1016/j.reprotox.2020.01.003. Epub 2020 Jan 14.
• [110] Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay. Toxicol In Vitro. 2015 Oct;29(7):1729-35.
• [111] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [112] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [113] Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 10;48(5):1563-75.
• [114] Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans. Endocr Res. 2004 Aug;30(3):387-94.
• [115] Estrogen synthesis in human colon cancer epithelial cells. J Steroid Biochem Mol Biol. 1999 Dec 31;71(5-6):223-30.
• [116] Effect of ellagic acid on the expression of human telomerase reverse transcriptase (hTERT) alpha+beta+ transcript in estrogen receptor-positive MCF-7 breast cancer cells. Clin Biochem. 2009 Sep;42(13-14):1358-62. doi: 10.1016/j.clinbiochem.2009.05.017. Epub 2009 Jun 6.
• [117] Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity. Anticancer Res. 2006 Sep-Oct;26(5A):3387-91.
• [118] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [119] Inhibitory effects of selenium on telomerase activity and hTERT expression in cadmium-transformed 16HBE cells. Biomed Environ Sci. 2007 Aug;20(4):307-12.
• [120] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [121] Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells. BMC Cancer. 2010 Jul 22;10:390. doi: 10.1186/1471-2407-10-390.
• [122] Analysis of telomerase activity and RNA expression in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid. Pediatr Blood Cancer. 2006 Apr;46(4):506-11. doi: 10.1002/pbc.20392.
• [123] Characterization of the functional and growth properties of long-term cell cultures established from a human somatostatinoma. Endocr Relat Cancer. 2006 Mar;13(1):79-93. doi: 10.1677/erc.1.00988.
• [124] Characterization of arsenic-induced cytogenetic alterations in acute promyelocytic leukemia cell line, NB4. Med Oncol. 2012 Jun;29(2):1209-16. doi: 10.1007/s12032-011-9946-4. Epub 2011 May 5.
• [125] Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Biol Interact. 2010 Jul 30;186(2):127-34. doi: 10.1016/j.cbi.2010.04.027. Epub 2010 May 21.
• [126] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [127] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [128] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [129] A comprehensive analysis of Wnt/beta-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 2018 Nov;40(1):331-339.
• [130] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [131] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [132] RLIP76 (RALBP1)-mediated transport of leukotriene C4 (LTC4) in cancer cells: implications in drug resistance. Int J Cancer. 2004 Dec 20;112(6):934-42. doi: 10.1002/ijc.20516.
• [133] Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin. Biochem Pharmacol. 2005 Aug 1;70(3):481-8. doi: 10.1016/j.bcp.2005.05.005.
• [134] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [135] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.